

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROFIT WARNING REDUCTION IN LOSS

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the Group’s unaudited consolidated management accounts for the year ended 31 December 2025 (the “**Year**”) and the information currently available to the Board, the Group is expected to record a net loss attributable to owners of the Company in the range of approximately RMB25.0 million to RMB30.0 million for the Year, representing a significant reduction of approximately 43.8% to 53.2% as compared to the net loss attributable to owners of the Company of approximately RMB53.4 million for the year ended 31 December 2024 (the “**Previous Year**”).

The expected reduction in loss is primarily attributable to the following factors: (i) the one-off non-cash fair value loss of approximately RMB29.5 million, which was recognised in the Previous Year as a result of the accounting reclassification of the Group’s equity interest in Beijing Kangchen Biological Technology Co., Ltd., did not recur in the Year; and (ii) the financial asset at fair value through profit or loss (representing the aforementioned equity interest) recorded fair value gains of approximately RMB14.0 million during the Year.

The Board highlights that a material portion of the expected improvement in the Group’s results for the Year arises from fair value gains on the financial asset at fair value through profit or loss. Such fair value changes are non-cash in nature, are assessed with reference to market parameters and assumptions, and do not represent recurring cash inflows from the Group’s core operating activities. The valuation of such assets may be subject to significant fluctuations due to changes in future valuation assumptions, market conditions, and other factors.

The Company is still in the process of finalising the annual results of the Group for the Year. The information contained in this announcement is based on the preliminary assessment of the Board with reference to the unaudited consolidated management accounts of the Group and the information currently available to the Board, which have not been reviewed or audited by the Company's auditors or the audit committee of the Board, and may be subject to adjustments. Details of the Group's financial performance for the Year will be disclosed in the annual results announcement, which is expected to be published by the end of March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 26 February 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.